Urothelial carcinoma in kidney transplant recipients and candidates : The French guidelines from CTAFU
Copyright © 2020. Published by Elsevier Masson SAS..
OBJECTIVE: To propose surgical recommendations for urothelial carcinoma management in kidney transplant recipients and candidates.
METHOD: A review of the literature (Medline) following a systematic approcah was conducted by the CTAFU regarding the epidemiology, screening, diagnosis and treatment of urothelial carcinoma in kidney transplant recipients and candidates for renal transplantation. References were assessed according to a predefined process to propose recommendations with levels of evidence.
RESULTS: Urothelial carcinomas occur in the renal transplant recipient population with a 3-fold increased incidence as compared with general population. While major risk factors for urothelial carcinomas are similar to those in the general population, aristolochic acid nephropathy and BK virus infection are more frequent risk factors in renal transplant recipients. As compared with general population, NMIBC in the renal transplant recipients are associated with earlier and higher recurrence rate. The safety and efficacy of adjuvant intravesical therapies have been reported in retrospective series. Treatment for localized MIBC in renal transplant recipients is based on radical cystectomy. In the candidate for a kidney transplant with a history of urothelial tumor, it is imperative to perform follow-up cystoscopies according to the recommended frequency, depending on the risk of recurrence and progression of NMIBC and to maintain this follow-up at least every six months up to transplantation whatever the level of risk of recurrence and progression. Based on current data, the present recommendations propose guidelines for waiting period before active wait-listing renal transplant candidates with a history of urothelial carcinoma.
CONCLUSION: The french recommendations from CTAFU should contribute to improve the management of urothelial carcinoma in renal transplant patients and renal transplant candidates by integrating both oncologic objectives and access to transplantation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie - 31(2021), 1 vom: 11. Jan., Seite 31-38 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : carcinome urothélial chez le patient transplanté rénal et le candidat à la transplantation rénale |
|---|
| Beteiligte Personen: |
Boissier, R [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carcinome urothélial |
|---|
| Anmerkungen: |
Date Completed 02.09.2021 Date Revised 02.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.purol.2020.04.028 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM319872602 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM319872602 | ||
| 003 | DE-627 | ||
| 005 | 20231225172358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.purol.2020.04.028 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1066.xml |
| 035 | |a (DE-627)NLM319872602 | ||
| 035 | |a (NLM)33423744 | ||
| 035 | |a (PII)S1166-7087(20)30683-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Boissier, R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Urothelial carcinoma in kidney transplant recipients and candidates |b The French guidelines from CTAFU |
| 246 | 3 | 3 | |a Recommandations françaises du Comité de transplantation de l’association française d’urologie (CTAFU) : carcinome urothélial chez le patient transplanté rénal et le candidat à la transplantation rénale |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.09.2021 | ||
| 500 | |a Date Revised 02.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020. Published by Elsevier Masson SAS. | ||
| 520 | |a OBJECTIVE: To propose surgical recommendations for urothelial carcinoma management in kidney transplant recipients and candidates | ||
| 520 | |a METHOD: A review of the literature (Medline) following a systematic approcah was conducted by the CTAFU regarding the epidemiology, screening, diagnosis and treatment of urothelial carcinoma in kidney transplant recipients and candidates for renal transplantation. References were assessed according to a predefined process to propose recommendations with levels of evidence | ||
| 520 | |a RESULTS: Urothelial carcinomas occur in the renal transplant recipient population with a 3-fold increased incidence as compared with general population. While major risk factors for urothelial carcinomas are similar to those in the general population, aristolochic acid nephropathy and BK virus infection are more frequent risk factors in renal transplant recipients. As compared with general population, NMIBC in the renal transplant recipients are associated with earlier and higher recurrence rate. The safety and efficacy of adjuvant intravesical therapies have been reported in retrospective series. Treatment for localized MIBC in renal transplant recipients is based on radical cystectomy. In the candidate for a kidney transplant with a history of urothelial tumor, it is imperative to perform follow-up cystoscopies according to the recommended frequency, depending on the risk of recurrence and progression of NMIBC and to maintain this follow-up at least every six months up to transplantation whatever the level of risk of recurrence and progression. Based on current data, the present recommendations propose guidelines for waiting period before active wait-listing renal transplant candidates with a history of urothelial carcinoma | ||
| 520 | |a CONCLUSION: The french recommendations from CTAFU should contribute to improve the management of urothelial carcinoma in renal transplant patients and renal transplant candidates by integrating both oncologic objectives and access to transplantation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Practice Guideline | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Carcinome urothélial | |
| 650 | 4 | |a Renal transplantation | |
| 650 | 4 | |a Transplantation rénale | |
| 650 | 4 | |a Urothelial carcinoma | |
| 650 | 4 | |a Waiting list | |
| 700 | 1 | |a Thuret, R |e verfasserin |4 aut | |
| 700 | 1 | |a Prudhomme, T |e verfasserin |4 aut | |
| 700 | 1 | |a Verhoest, G |e verfasserin |4 aut | |
| 700 | 1 | |a Bessede, T |e verfasserin |4 aut | |
| 700 | 1 | |a Branchereau, J |e verfasserin |4 aut | |
| 700 | 1 | |a Goujon, A |e verfasserin |4 aut | |
| 700 | 1 | |a Drouin, S |e verfasserin |4 aut | |
| 700 | 1 | |a Boutin, J-M |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzillet, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Roupret, M |e verfasserin |4 aut | |
| 700 | 1 | |a Méjean, A |e verfasserin |4 aut | |
| 700 | 1 | |a Timsit, M-O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie |d 1997 |g 31(2021), 1 vom: 11. Jan., Seite 31-38 |w (DE-627)NLM012649481 |x 1166-7087 |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2021 |g number:1 |g day:11 |g month:01 |g pages:31-38 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.purol.2020.04.028 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2021 |e 1 |b 11 |c 01 |h 31-38 | ||